Cargando…

JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342982/
https://www.ncbi.nlm.nih.gov/pubmed/29562474
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.016
_version_ 1783555656630927360
collection PubMed
description
format Online
Article
Text
id pubmed-7342982
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73429822020-07-16 JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 Zhonghua Xue Ye Xue Za Zhi 病例报告 Editorial office of Chinese Journal of Hematology 2018-03 /pmc/articles/PMC7342982/ /pubmed/29562474 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.016 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 病例报告
JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
title JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
title_full JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
title_fullStr JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
title_full_unstemmed JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
title_short JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
title_sort jak2v617f突变和bcr-abl融合基因双阳性骨髓增殖性肿瘤二例
topic 病例报告
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342982/
https://www.ncbi.nlm.nih.gov/pubmed/29562474
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.016
work_keys_str_mv AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì
AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì